Vorinostat interferes with Wnt and NF-kappaB pathways in the M-07e cell line.
Galimberti
S
S
Canestraro
M
M
Maffei
R
R
Marasca
R
R
Guerrini
F
F
Piaggi
S
S
Ciabatti
E
E
Petrini
M
M
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D024202:Electrophoretic Mobility Shift Assay; D005434:Flow Cytometry; D020869:Gene Expression Profiling; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology*; D007947:Leukemia, Megakaryoblastic, Acute / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism*; D020411:Oligonucleotide Array Sequence Analysis; D015398:Signal Transduction; D014407:Tumor Cells, Cultured; D000077337:Vorinostat; D051153:Wnt Proteins / Q000378:metabolism*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D016328:NF-kappa B; D051153:Wnt Proteins; D000077337:Vorinostat